AcelRx Pharmaceuticals (NASDAQ:ACRX): AcelRx shed nearly 13% from Dec. 5-7, after the company announced a secondary offering of 12.5 million shares at $3.31 per share ??? a total of $41.38 million before fees ??? to help fund operations and other costs involved with an FDA application for its NanoTab system, a form of post-operative pain control.